Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aladin WD repeat nucleoporin is a protein encoded by the AAAS gene and belongs to the nucleoporin family, acting as a crucial gatekeeper at the nuclear pore complex, regulating molecular transport between the nucleus and the cytoplasm. It contains WD-repeat motifs enabling its multiple protein-protein interactions, including with lamins of the nuclear envelope, and is enriched in endocrine and nervous tissues. Mutations lead to Triple A syndrome, a rare autosomal recessive disorder characterized by achalasia, adrenal insufficiency, and alacrima, resulting primarily from impaired nucleocytoplasmic transport and compromised DNA repair, especially under oxidative stress. There are no drugs that target Aladin directly; instead, genetic testing for AAAS mutations confirms the diagnosis and informs clinical management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aladin WD repeat nucleoporin (AAAS).